NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis $49.63 +0.29 (+0.59%) Closing price 04:00 PM EasternExtended Trading$50.44 +0.81 (+1.64%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Soleno Therapeutics Stock (NASDAQ:SLNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$48.64▼$50.4950-Day Range$42.54▼$51.3352-Week Range$36.61▼$60.92Volume749,662 shsAverage Volume522,969 shsMarket Capitalization$2.28 billionP/E RatioN/ADividend YieldN/APrice Target$71.20Consensus RatingBuy Company OverviewSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More… Remove Ads Soleno Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreSLNO MarketRank™: Soleno Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 161st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.72) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -14.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -14.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 9.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.37% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 5.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted14.37% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 5.95%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.47 News SentimentSoleno Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Soleno Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows4 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $790,119.00 in company stock.Percentage Held by Insiders12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Stock News HeadlinesNotable Thursday Option Activity: SLNO, ABNB, RKTMarch 15 at 9:54 AM | nasdaq.com3SLNO : What the Options Market Tells Us About Soleno TherapeuticsMarch 13, 2025 | benzinga.comA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....March 17, 2025 | Banyan Hill Publishing (Ad)Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $71.20 Average Price Target from BrokeragesMarch 9, 2025 | americanbankingnews.comFY2025 EPS Estimates for SLNO Lowered by Cantor FitzgeraldMarch 8, 2025 | americanbankingnews.comHC Wainwright Issues Negative Estimate for SLNO EarningsMarch 8, 2025 | americanbankingnews.comSoleno Therapeutics resumed with a Buy at StifelMarch 5, 2025 | markets.businessinsider.comSoleno Therapeutics reports Q4 EPS ($1.27) vs. (33c) last yearFebruary 27, 2025 | markets.businessinsider.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How have SLNO shares performed this year? Soleno Therapeutics' stock was trading at $44.95 at the beginning of 2025. Since then, SLNO shares have increased by 10.4% and is now trading at $49.63. View the best growth stocks for 2025 here. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its quarterly earnings data on Wednesday, March, 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.41. When did Soleno Therapeutics' stock split? Soleno Therapeutics shares reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Soleno Therapeutics' major shareholders? Top institutional investors of Soleno Therapeutics include Janus Henderson Group PLC (12.03%), Nantahala Capital Management LLC (9.11%), Adage Capital Partners GP L.L.C. (6.44%) and Avoro Capital Advisors LLC (5.86%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, Jack W Schuler, James H Mackaness and Kristen Yen. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings3/05/2025Today3/17/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:SLNO CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$71.20 High Stock Price Target$74.00 Low Stock Price Target$67.00 Potential Upside/Downside+43.8%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.99% Return on Assets-55.21% Debt Debt-to-Equity RatioN/A Current Ratio17.26 Quick Ratio17.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book9.60Miscellaneous Outstanding Shares45,857,000Free Float37,814,000Market Cap$2.27 billion OptionableOptionable Beta-1.70 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:SLNO) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.